Migraine management goes beyond acute symptom control and may also include preventive strategies for patients with a significant disease burden. Although triptans remain the recommended first-line treatment for acute migraine, more than 30% of patients cannot use them or do not achieve sufficient relief. Calcitonin gene-related peptide (CGRP) receptor antagonists have therefore emerged as a promising alternative treatment option.
Autoren
- Aneta Dehn
Publikation
- InFo NEUROLOGIE & PSYCHIATRIE
Related Topics
You May Also Like
- Ischemic stroke: Are smaller or larger brain arteries affected?
Recent study findings on intravenous lysis therapy with fibrinolytic agents
- Interview
“On par with the gold standards for trauma”
- Psychology: Emotional Freedom Techniques (EFT)
Emotional Healing Through Tapping
- Systemic Lupus (SLE): What Does the Diagnosis and Treatment Toolbox Have to Offer?
Treat-to-Target – Consensus Recommendations for GC Tapering and the Use of DMARDs
- Interstitial Lung Diseases
Update on Idiopathic Pulmonary Fibrosis
- Psychedelic-assisted therapy
Current status of PAT
- Psoriasis and Obesity: Effects of Incretin-Based Therapies
Clinical trials shed light on the potential of semaglutide, liraglutide, and tirzepatide
- Non-small-cell lung cancer (NSCLC)